<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330303</url>
  </required_header>
  <id_info>
    <org_study_id>114073</org_study_id>
    <nct_id>NCT01330303</nct_id>
  </id_info>
  <brief_title>SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin</brief_title>
  <official_title>Randomized, Two-period, Cross-over, Bioequivalence Study on Tamsulosin Hydrochloride 0,4 mg Prolonged Release Hard Gelatin Capsule Versus SECOTEX® (Tamsulosin Hydrochloride) 0,4 mg Prolonged Release Hard Gelatin Capsule Healthy Male Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments,
      02 sequences, and 02 periods, in which the volunteers receive, in each period, the test
      formulation or the reference formulation, under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments,
      02 sequences, and 02 periods, in which the volunteers receive, in each period, the test
      formulation or the reference formulation, under fed conditions.

      The treatment's sequence attributed to each volunteer on the study period is determined by a
      randomization list, which is generated by PROC PLAN from SAS version 9.1.3 system.

      The formulations will be administered as a single oral dose followed by blood collections
      between, at least, 3 to 5 half-lives. The treatment's periods may obey a minimum interval of
      7 half lives between them (period for drug's whole elimination by the organism).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2009</start_date>
  <completion_date type="Actual">December 22, 2009</completion_date>
  <primary_completion_date type="Actual">December 22, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-t</measure>
    <time_frame>Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)</time_frame>
    <description>The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration) was calculated using the trapezoidal method. This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)</time_frame>
    <description>The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug) was calculated using the trapezoidal method. This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)</time_frame>
    <description>Cmax is defined as the maximum or &quot;peak&quot; concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>tamsulosin - Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference drug administration followed by Test drug administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tamsulosin - Test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test drug administration followed by Reference drug administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference formulation</intervention_name>
    <description>SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)</description>
    <arm_group_label>tamsulosin - Reference</arm_group_label>
    <arm_group_label>tamsulosin - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test formulation</intervention_name>
    <description>tamsulosin hydrochloride 0,4 mg (Synthon BV)</description>
    <arm_group_label>tamsulosin - Reference</arm_group_label>
    <arm_group_label>tamsulosin - Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        EXCLUSION CRITERIA:

          -  The volunteer has a known hypersensitivity to the study drug (tamsulosin
             hydrochloride) or to compounds chemically related;

          -  History or presence of hepatic or gastrointestinal illnesses, or other condition that
             interferes over the drug's absorption, distribution, excretion or metabolism;

          -  History of hepatic, renal, pulmonary, gastrointestinal, epileptic, hematologic or
             psychiatric illness; hypo or hypertension of any etiologic that needs pharmacologic
             treatment; has history or had myocardial infarction, angina and/or heart
             insufficiency;

          -  Non-recommended electrocardiographic findings, according investigator criteria;

          -  The results of the laboratory exams are out of the values considered as normal
             according this protocol's rules, unless that they are considered as clinically
             irrelevant by the investigator;

          -  Volunteer is a smoker;

          -  The volunteer ingests more than 5 cups of coffee or tea a day;

          -  Has history of alcohol or drugs abuse;

          -  History of serious adverse reactions or hypersensitivity to any drug;

          -  Use of any regular drug within the 02 weeks that preceded study's initiation or
             treatment within the 03 previous months, that preceded study's initiation, with any
             drug that presents toxic, or volunteer consumed inductive drugs and/or enzymatic
             inhibitor (CYP450 - hepatic), within the 04 weeks that preceded the study's
             initiation;

          -  Volunteer was hospitalized for any reason within the 08 weeks of the beginning of the
             study's first period of treatment and the post study assessment date;

          -  Participation in any experimental study or ingestion of any experimental drug within
             the 06 previous months;

          -  Volunteer consumed alcohol in 48 hours prior to the admission to the study or consumed
             foods or beverages that contain grapefruit until 07 days previous to each study
             period.

        INCLUSION CRITERIA:

          -  Male;

          -  Age between 18 and 50 years;

          -  Body mass index ≥ 19 and ≤28,5;

          -  Good health conditions or without significant illness, by judgment of a legally
             qualified professional, according the rules defined in Protocol, and according the
             following evaluations: clinical history, pressure and pulse measures, physical and
             psychological exam, ECG, and additional laboratory exams;

          -  Capable to understand the study's nature and aim, including the risks and adverse
             effects and with intention to cooperate with the researcher and to act in compliance
             with the requirements of the whole assay; this will be confirmed by the Informed
             Consent's signature.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/114073?search=study&amp;search_terms=114073#rs</url>
    <description>Results for study 114073 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <results_first_submitted>March 10, 2011</results_first_submitted>
  <results_first_submitted_qc>March 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2011</results_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>tamsulosin hydrochloride</keyword>
  <keyword>Fed administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product in Period 1; Reference Product in Period 2</title>
          <description>Test product: tamsulosin hydrochloride 0.4 milligrams (mg) prolonged release hard gelatin capsule in Period 1; followed by a 7-day washout period during which no medication was administered; followed by reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in Period 2</description>
        </group>
        <group group_id="P2">
          <title>Reference Product in Period 1; Test Product in Period 2</title>
          <description>Reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: tamsulosin hydrochloride 0.4 mg prolonged release hard gelatin capsule in Period 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>7-Day Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants Receiving Both Test Product and Reference Product</title>
          <description>Participants receiving either test product: tamsulosin hydrochloride 0.4 mg prolonged release hard gelatin capsule in Period 1; followed by reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in Period 2 or reference product in Period 1 and test product in Period 2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.20" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mulatto</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-t</title>
        <description>The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration) was calculated using the trapezoidal method. This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.</description>
        <time_frame>Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Test product: tamsulosin hydrochloride 0.4 mg prolonged release hard gelatin capsule in both periods</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in both periods</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-t</title>
          <description>The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration) was calculated using the trapezoidal method. This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; ml, milliliter.</description>
          <population>Participants who completed the study</population>
          <units>ng per hour per ml (ng.h/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229.87" spread="119.88"/>
                    <measurement group_id="O2" value="220.85" spread="98.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This is a bioequivalence study performed to support the register of tamsulosin hydrochloride, produced by Synthon BV, as a branded generic, to be marketed by GlaxoSmithKline Brasil Ltda., according to the requirements of the Brazilian Regulatory Agency – National Agency of Sanitary Surveillance (ANVISA).</non_inferiority_desc>
            <param_type>Ratio T formulation/R formulation</param_type>
            <param_value>101.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>94.91</ci_lower_limit>
            <ci_upper_limit>109.39</ci_upper_limit>
            <estimate_desc>The ratios between the geometric means of the test (T) and reference (R) formulations were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-infinity</title>
        <description>The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug) was calculated using the trapezoidal method. This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.</description>
        <time_frame>Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Test product: tamsulosin hydrochloride 0.4 mg prolonged release hard gelatin capsule in both periods</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in both period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity</title>
          <description>The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug) was calculated using the trapezoidal method. This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.</description>
          <population>Participants who completed the study</population>
          <units>ng.h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.87" spread="125.56"/>
                    <measurement group_id="O2" value="228.36" spread="103.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This is a bioequivalence study performed to support the register of tamsulosin hydrochloride, produced by Synthon BV, as a branded generic, to be marketed by GlaxoSmithKline Brasil Ltda., according to the requirements of the Brazilian Regulatory Agency – National Agency of Sanitary Surveillance (ANVISA).</non_inferiority_desc>
            <param_type>Ratio T formulation/R formulation</param_type>
            <param_value>101.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.00</ci_lower_limit>
            <ci_upper_limit>109.33</ci_upper_limit>
            <estimate_desc>The ratios between the geometric means of the test (T) and reference (R) formulations were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Cmax is defined as the maximum or “peak” concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.</description>
        <time_frame>Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Test product: tamsulosin hydrochloride 0.4 mg prolonged release hard gelatin capsule in both periods</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in both period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Cmax is defined as the maximum or “peak” concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.</description>
          <population>Participants who completed the study</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.06" spread="6.22"/>
                    <measurement group_id="O2" value="14.88" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>This is a bioequivalence study performed to support the register of tamsulosin hydrochloride, produced by Synthon BV, as a branded generic, to be marketed by GlaxoSmithKline Brasil Ltda., according to the requirements of the Brazilian Regulatory Agency – National Agency of Sanitary Surveillance (ANVISA).</non_inferiority_desc>
            <param_type>Ratio T formulation/R formulation</param_type>
            <param_value>94.04</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>86.33</ci_lower_limit>
            <ci_upper_limit>102.44</ci_upper_limit>
            <estimate_desc>The ratios between the geometric means of the test (T) and reference (R) formulations were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Test Product in Period 1; Reference Product in Period 2</title>
          <description>Test product: tamsulosin hydrochloride 0.4 milligrams (mg) prolonged release hard gelatin capsule in Period 1; followed by a 7-day washout period during which no medication was administered; followed by reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in Period 2</description>
        </group>
        <group group_id="E2">
          <title>Reference Product in Period 1; Test Product in Period 2</title>
          <description>Reference product: SECOTEX (tamsulosin hydrochloride) 0.4 mg prolonged release hard gelatin capsule in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: tamsulosin hydrochloride 0.4 mg prolonged release hard gelatin capsule in Period 2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Ds Navigator</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Serum glutamic-pyruvic increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gamma glutamyl transferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Glucose high</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Serum urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Serum bilirubin increased (total and indirect)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Postural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

